Evidence map›Paper›PMID 33472616›Full record

ArticleBMC biology2021

No detectable alloreactive transcriptional responses under standard sample preparation conditions during donor-multiplexed single-cell RNA sequencing of peripheral blood mononuclear cells.

Christopher S McGinnis, David A Siegel, Guorui Xie, George Hartoularos, Mars Stone, Chun J Ye, Zev J Gartner, Nadia R Roan, Sulggi A Lee

Open access · goldAbstract read
In one paragraph

Article in BMC biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. deMULTIplex2: robust sample demultiplexing for scRNA-seq.bioRxiv : the preprint server for biology · 2023
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Christopher S McGinnisDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6923-9341
David A SiegelDepartment of Medicine, Division of HIV/AIDS, UCSF, San Francisco, CA, USA.
Guorui XieGladstone Institute of Virology, San Francisco, CA, USA.
George HartoularosInstitute for Human Genetics, UCSF, San Francisco, CA, USA.
Mars StoneDepartment of Laboratory Medicine, UCSF, San Francisco, CA, USA.
Chun J YeInstitute for Human Genetics, UCSF, San Francisco, CA, USA.
Zev J GartnerDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Nadia R Roan *Gladstone Institute of Virology, San Francisco, CA, USA. nadia.roan@ucsf.edu.
Sulggi A Lee *Department of Medicine, Division of HIV/AIDS, UCSF, San Francisco, CA, USA. sulggi.lee@ucsf.edu.
University of California, San Francisco · USGladstone Institutes · USSan Francisco AIDS Foundation · US

Funding

GENETICS OF EUCARYOTIC AND PROCARYOTIC ORGANISMST32GM007810 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ASHRAFI, KAVEH, NARLIKAR, GEETA J · 1985 to 2020
$15.1M
RESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGYP30AR070155 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary C Nakamura · 2016 to 2026
$8.2M
BMI Bioinformatics Training GrantsT32GM067547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HERNANDEZ, RYAN D. · 2003 to 2022
$6.6M
Host genetic predictors of plasma IL-1b levels and pharmacogenomics of in vivo IL-1b blockade during treated HIV diseaseR01AI143464 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, SULGGI ANGELA · 2019 to 2023
$4.0M
Integrative approach to heterogeneity in breast cancer metastasisU01CA199315 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI, SPELLMAN, PAUL T. · 2016 to 2020
$3.2M
Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV diseaseR61DA047024 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, SULGGI ANGELA · 2018 to 2021
$2.7M
Total synthesis of the human mammary glandDP2HD080351 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GARTNER, ZEV JORDAN · 2013 to 2013
$2.4M
Elucidating the mechanism of progesterone-induced permissivity in the upperfemale reproductive tractR01AI127219 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2016 to 2020
$2.1M
MULTIseq: multiplexing massively parallel single cell transcriptional analysis across time, space, and conditionsR01GM135462 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GARTNER, ZEV JORDAN · 2019 to 2022
$1.3M
Universal Sample Multiplexing for Single Cell AnalysisR33CA247744 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GARTNER, ZEV JORDAN · 2021 to 2023
$1.2M
NCI NIH HHS R33 CA247744NCI NIH HHS U01 CA199315NIAID NIH HHS R01 AI127219NIAID NIH HHS R01 AI143464NIAMS NIH HHS P30 AR070155NICHD NIH HHS DP2 HD080351NIDA NIH HHS R61 DA047024NIGMS NIH HHS R01 GM135462NIGMS NIH HHS T32 GM007810NIGMS NIH HHS T32 GM067547NIH HHS DP2 HD080351-01NIH HHS R01AI127219NIH HHS R01AI14777NIH HHS U01CA199315
6 · The paper itself

Abstract

backgroundSingle-cell RNA sequencing (scRNA-seq) provides high-dimensional measurements of transcript counts in individual cells. However, high assay costs and artifacts associated with analyzing samples across multiple sequencing runs limit the study of large numbers of samples. Sample multiplexing technologies such as MULTI-seq and antibody hashing using single-cell multiplexing kit (SCMK) reagents (BD Biosciences) use sample-specific sequence tags to enable individual samples to be sequenced in a pooled format, markedly lowering per-sample processing and sequencing costs while minimizing technical artifacts. Critically, however, pooling samples could introduce new artifacts, partially negating the benefits of sample multiplexing. In particular, no study to date has evaluated whether pooling peripheral blood mononuclear cells (PBMCs) from unrelated donors under standard scRNA-seq sample preparation conditions (e.g., 30 min co-incubation at 4 °C) results in significant changes in gene expression resulting from alloreactivity (i.e., response to non-self). The ability to demonstrate minimal to no alloreactivity is crucial to avoid confounded data analyses, particularly for cross-sectional studies evaluating changes in immunologic gene signatures.

resultsHere, we applied the 10x Genomics scRNA-seq platform to MULTI-seq and/or SCMK-labeled PBMCs from a single donor with and without pooling with PBMCs from unrelated donors for 30 min at 4 °C. We did not detect any alloreactivity signal between mixed and unmixed PBMCs across a variety of metrics, including alloreactivity marker gene expression in CD4+ T cells, cell type proportion shifts, and global gene expression profile comparisons using Gene Set Enrichment Analysis and Jensen-Shannon Divergence. These results were additionally mirrored in publicly-available scRNA-seq data generated using a similar experimental design. Moreover, we identified confounding gene expression signatures linked to PBMC preparation method (e.g., Trima apheresis), as well as SCMK sample classification biases against activated CD4+ T cells which were recapitulated in two other SCMK-incorporating scRNA-seq datasets.

conclusionsWe demonstrate that (i) mixing PBMCs from unrelated donors under standard scRNA-seq sample preparation conditions (e.g., 30 min co-incubation at 4 °C) does not cause an allogeneic response, and (ii) that Trima apheresis and PBMC sample multiplexing using SCMK reagents can introduce undesirable technical artifacts into scRNA-seq data. Collectively, these observations establish important benchmarks for future cross-sectional immunological scRNA-seq experiments.

Indexed as

TranscriptomeHumansLeukocytes, MononuclearSequence Analysis, RNASingle-Cell AnalysisSpecimen HandlingAlloreactivityPBMCsSample multiplexingSample preparationscRNA-seq

Identifiers

PMID33472616
PMCPMC7816397
OpenAlexW3121654298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.